John Butler, Akebia CEO

Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

Ake­bia Ther­a­peu­tics is back with more da­ta on its ex­per­i­men­tal ane­mia drug vadadu­s­tat fol­low­ing a CRL from the FDA last year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.